This webcast features: Tim Kelly, CEO, Oxford Biomedica Solutions. It is now fully apparent that product quality is critical to the performance of gene therapy products. In turn, regulatory expectations have risen dramatically for the quality of the viral vectors that are used to deliver such therapies. That said, yields from viral-vector production processes tend to be much lower than those for conventional protein products. The ability to address all aspects of product quality while still achieving high vector output…

This webcast features: Graziella Piras, PhD, Bioprocessing Segment Director, 908 Devices. Unlike biotherapeutic proteins that benefit from decades of development and manufacturing experience, cell and gene therapies are still young. Producing these diverse therapeutics requires that various cells be used based on the specific application. Since various cells have different requirements, the medium used to culture them must be designed for optimal growth and/or productivity of each cell type. When the composition of the cell culture medium does not match…

This webcast features: Yiyu Dong, PhD, Associate Director of Viral Vector Process Technology Development (VVPTD), WuXi Advanced Therapies. Due to their capability for long-term transgene expression, large packaging capacity and ability to transduce postmitotic and quiescent cells, lentiviral vectors have become increasingly popular gene delivery tools for cell and gene therapies in recent years. However, capacity for lentiviral vector manufacture is a major industry bottleneck. WuXi Advanced Therapies has developed a lentiviral suspension manufacturing platform using OXGENE’s XLenti™ packaging plasmids.…